Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Gene Therapy Shows Early Promise for Treating Parkinson’s

By Ryan Bushey | December 12, 2016

A biotech startup is inching closer to refining a treatment for Parkinson’s disease.

Voyager Therapeutics is testing an experimental gene therapy that could boost Parkinson’s patients’ responses to levodopa—an old medication that can manage the symptoms of this disease in its early stages.

Levodopa ends up losing its efficacy over time because an enzyme called aromatic L-amino acid decarboxylase (AADC) begins to die off, wrote Business Insider. Levodopa needs this enzyme to convert to dopamine, which helps prolong the arrival of debilitating symptoms like a decline in motor functions.

Voyager’s candidate is inserted via MRI technology into the patient’s putamen, an area of the brain that struggles to produce dopamine for Parkinson’s patients, where it begins to essentially manufacture more AADC.

A small trial testing this technology on 10 patients with an advanced form of the condition yielded some promising results.

The drug was able to increase AADC activity by 56 percent and lowered levodopa dosages by 34 percent in the first six months of the study, according to FierceBiotech.

“Levodopa has been the gold-standard treatment for Parkinson’s for decades, but it has limitations.  Enhancing a patient’s response to this therapy represents an important development for those who suffer from the advanced stages of this disease, and we are glad to see the continued progress of this program,” said Todd Scherer, Ph.D., the CEO of the Michael J. Fox Foundation, in a statement.

His organization provided funding for part of this research.

The injection process initially appeared to be well tolerated while further follow-up suggested the treatment’s effects lasted at least another 12 months.

Next, Voyager needs to prove its invention can work for a larger group of patients and last longer than one year. It’s expected to finish enrollment for another study in early 2017.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE